227 related articles for article (PubMed ID: 15488941)
1. Investigation of the mechanisms of anti-complement activity in Ixodes ricinus ticks.
Lawrie CH; Sim RB; Nuttall PA
Mol Immunol; 2005 Jan; 42(1):31-8. PubMed ID: 15488941
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
Sahu A; Kay BK; Lambris JD
J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumour necrosis factor-alpha activity in Ixodes ricinus saliva.
Koník P; Slavíková V; Salát J; Reznícková J; Dvoroznáková E; Kopecký J
Parasite Immunol; 2006 Dec; 28(12):649-56. PubMed ID: 17096644
[TBL] [Abstract][Full Text] [Related]
4. Formation of covalently linked C3-C3 dimers on IgG immune aggregates.
Barrio E; Antón LC; Marqués G; Sánchez A; Vivanco F
Eur J Immunol; 1991 Feb; 21(2):343-9. PubMed ID: 1999223
[TBL] [Abstract][Full Text] [Related]
5. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome.
Sartz L; Olin AI; Kristoffersson AC; Ståhl AL; Johansson ME; Westman K; Fremeaux-Bacchi V; Nilsson-Ekdahl K; Karpman D
J Immunol; 2012 Feb; 188(4):2030-7. PubMed ID: 22250080
[TBL] [Abstract][Full Text] [Related]
6. Interference of propamidine with binding of the fifth component of complement to surface-fixed C3b, and with C5 activation.
Vogt W; Schmidt G; Hinsch B
Immunology; 1979 Jan; 36(1):139-43. PubMed ID: 422225
[TBL] [Abstract][Full Text] [Related]
7. Activated factor B (Bb) of the alternative pathway of complement activation cleaves and activates plasminogen.
Sundsmo JS; Wood LM
J Immunol; 1981 Sep; 127(3):877-80. PubMed ID: 6911148
[TBL] [Abstract][Full Text] [Related]
8. Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase.
Moore FD; Austen KF; Fearon DT
J Immunol; 1982 Mar; 128(3):1302-6. PubMed ID: 6915957
[TBL] [Abstract][Full Text] [Related]
9. Complement 1 inhibitor is a regulator of the alternative complement pathway.
Jiang H; Wagner E; Zhang H; Frank MM
J Exp Med; 2001 Dec; 194(11):1609-16. PubMed ID: 11733575
[TBL] [Abstract][Full Text] [Related]
10. Interactions of human complement component C3 with factor B and with complement receptors type 1 (CR1, CD35) and type 3 (CR3, CD11b/CD18) involve an acidic sequence at the N-terminus of C3 alpha'-chain.
Taniguchi-Sidle A; Isenman DE
J Immunol; 1994 Dec; 153(11):5285-302. PubMed ID: 7963581
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of the intracellular killing of Staphylococcus aureus by monocytes: regulation by immunoglobulin G and complement components C3/C3b and B/Bb.
Leijh PC; van den Barselaar MT; Daha MR; van Furth R
J Immunol; 1982 Jul; 129(1):332-7. PubMed ID: 6979568
[TBL] [Abstract][Full Text] [Related]
12. Modulation of human lymphocyte proliferation by salivary gland extracts of ixodid ticks (Acari: Ixodidae): effect of feeding stage and sex.
Rolníková T; Kazimírová M; Buc M
Folia Parasitol (Praha); 2003 Dec; 50(4):305-12. PubMed ID: 14971600
[TBL] [Abstract][Full Text] [Related]
13. Biochemical and functional characterization of Salp20, an Ixodes scapularis tick salivary protein that inhibits the complement pathway.
Tyson K; Elkins C; Patterson H; Fikrig E; de Silva A
Insect Mol Biol; 2007 Aug; 16(4):469-79. PubMed ID: 17651236
[TBL] [Abstract][Full Text] [Related]
14. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells.
Schwendinger MG; Spruth M; Schoch J; Dierich MP; Prodinger WM
J Immunol; 1997 Jun; 158(11):5455-63. PubMed ID: 9164968
[TBL] [Abstract][Full Text] [Related]
15. Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b.
DiLillo DJ; Pawluczkowycz AW; Peng W; Kennedy AD; Beum PV; Lindorfer MA; Taylor RP
Mol Immunol; 2006 Mar; 43(7):1010-9. PubMed ID: 15961157
[TBL] [Abstract][Full Text] [Related]
16. The cofactors required by C3 nephritic factor to generate a C3 convertase in vitro.
Amos N; Sissons JG; Girard JF; Lachmann PJ; Peters DK
Clin Exp Immunol; 1976 Jun; 24(3):474-82. PubMed ID: 939051
[TBL] [Abstract][Full Text] [Related]
17. Trypanosoma lewisi: restriction of alternative complement pathway C3/C5 convertase activity.
Sturtevant JE; Balber AE
Exp Parasitol; 1987 Jun; 63(3):260-71. PubMed ID: 3556206
[TBL] [Abstract][Full Text] [Related]
18. Cooperation between MASP-1 and MASP-2 in the generation of C3 convertase through the MBL pathway.
Møller-Kristensen M; Thiel S; Sjöholm A; Matsushita M; Jensenius JC
Int Immunol; 2007 Feb; 19(2):141-9. PubMed ID: 17182967
[TBL] [Abstract][Full Text] [Related]
19. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases.
Rooijakkers SH; Ruyken M; Roos A; Daha MR; Presanis JS; Sim RB; van Wamel WJ; van Kessel KP; van Strijp JA
Nat Immunol; 2005 Sep; 6(9):920-7. PubMed ID: 16086019
[TBL] [Abstract][Full Text] [Related]
20. Mutations of the type A domain of complement factor B that promote high-affinity C3b-binding.
Hourcade DE; Mitchell LM; Oglesby TJ
J Immunol; 1999 Mar; 162(5):2906-11. PubMed ID: 10072540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
